Bioavailability enhancement of glucosamine hydrochloride by chitosan

International Journal of Pharmaceutics

Volumn 455, Issue 1-2, 2013, Pages 365-373

  Qian, Shuai ^a,b   Zhang, Qizhi ^b,c   Wang, Yanfeng ^b   Lee, Benjamin ^b   Betageri, Guru V ^d   Chow, Moses S S ^d   Huang, Min ^e   Zuo, Zhong ^a  

^a Prince of Wales Hospital   (Hong Kong)

^b Hong Kong Science Park   (Hong Kong)

^c FUDAN UNIVERSITY   (China)

^d WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

^e SUN YAT SEN UNIVERSITY   (China)

Author keywords

Bioavailability; Caco 2 cell model; Chitosan; Glucosamine; Permeability

Indexed keywords

CHITOSAN; GLUCOSAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CELL STRAIN CACO 2; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG ABSORPTION; DRUG BIOAVAILABILITY; IN VITRO STUDY; INTESTINE ABSORPTION; INTESTINE MUCOSA PERMEABILITY; MALE; MAXIMUM ALLOWABLE CONCENTRATION; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; TABLET FORMULATION;

BIOAVAILABILITY; CACO-2 CELL MODEL; CHITOSAN; GLUCOSAMINE; PERMEABILITY;

ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL SURVIVAL; CHITOSAN; DIETARY SUPPLEMENTS; DOGS; GLUCOSAMINE; HUMANS; INTESTINAL ABSORPTION; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84883851893     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2013.06.055     Document Type: Article

References (67)

1. Adebowale, A., Du, J.P., Liang, Z.M., Leslie, J.L., Eddington, N.D., 2002. The bioavailability and pharmacokinetics of glucosamine hydrochloride and low molecular weight chondroitin sulfate after single and multiple doses to beagle dogs. Biopharm. Drug Dispos. 23, 217-225.
2. Aghazadeh-Habashi, A., Jamali, F., 2011. The glucosamine controversy; a pharmacokinetic issue. J. Pharm. Pharm. Sci. 14, 264-273.
3. Aghazadeh-Habashi, A., Sattari, S., Pasutto, F.M., Jamali, F., 2002. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J. Pharm. Pharm. Sci. 5, 181-184.
4. Anderberg, E.K., Artursson, P., 1993. Epithelial transport of drugs in cell-culture. VIII: effects of sodium dodecyl-sulfate on cell-membrane and tight junction permeability in human intestinal epithelial (Caco-2) cells. J. Pharm. Sci. 82, 392-398. (Pubitemid 23150434)
5. Artursson, P., Lindmark, T., Davis, S.S., Illum, L., 1994. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11, 1358-1361. (Pubitemid 24287420)
6. Artursson, P., Palm, K., Luthman, K., 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46, 27-43.
7. Aungst, B.J., 2012. Absorption enhancers: applications and advances. AAPS J. 14, 10-18.
8. Chae, S.Y., Jang, M.K., Nah, J.W., 2005. Influence of molecular weight on oral absorption of water soluble chitosans. J. Control. Release 102, 383-394. (Pubitemid 40093761)
9. Dodane, V., Khan, M.A., Merwin, J.R., 1999. Effect of chitosan on epithelial permeability and structure. Int. J. Pharm. 182, 21-32. (Pubitemid 29229791)
10. Dressman, J.B., Berardi, R.R., Dermentzoglou, L.C., Russell, T.L., Schmaltz, S.P., Barnett, J.L., Jarvenpaa, K.M., 1990. Upper gastrointestinal (GI) pH in young, healthy men and women. Pharm. Res. 7, 756-761. (Pubitemid 20278376)
11. Fernandez-Urrusuno, R., Calvo, P., Remunan-Lopez, C., Vila-Jato, J.L., Alonso, M.J., 1999. Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm. Res. 16, 1576-1581. (Pubitemid 29510555)
12. Finney, D.J., 1971. Probit Analysis: A Statistical Treatment of the Sigmoid Response Curve. Cambridge University Press, Cambridge, UK.
13. Fong, Y.K., Li, C.R., Wo, S.K., Wang, S., Zhou, L., Zhang, L., Lin, G., Zuo, Z., 2012. In vitro and in situ evaluation of herb-drug interactions during intestinal metabolism and absorption of baicalein. J. Ethnopharmacol. 141, 742-753.
14. Furuse, M., 2010. Introduction: claudins, tight junctions, and the paracellular barrier. In: Alan, S.L.Y. (Ed.), Current Topics in Membranes, vol. 65. Academic Press, London, UK, pp. 1-19 (Chapter 1).
15. Gao, Y., He, L., Katsumi, H., Sakane, T., Fujita, T., Yamamoto, A., 2008. Improvement of intestinal absorption of insulin and water-soluble macromolecular compounds by chitosan oligomers in rats. Int. J. Pharm. 359, 70-78.
16. Holme, H.K., Hagen, A., Dornish, M., 2000. Influence of chitosans on permeability of human intestinal epithelial (Caco-2) cells: the effect of molecular weight, degree of deacetylation and exposure time. In: Peter, M.G., Domard, A., Muzzarelli, R.A.A. (Eds.), Advances in Chitin Science, vol. 4. Universität Potsdam, Schmergow, Germany, pp. 259-265.
17. Hong, S., Leroueil, P.R., Janus, E.K., Peters, J.L., Kober, M.M., Islam, M.T., Orr, B.G., Baker Jr., J.R., Banaszak Holl, M.M., 2006. Interaction of polycationic polymers with supported lipid bilayers and cells: nanoscale hole formation and enhanced membrane permeability. Bioconjug. Chem. 17, 728-734. (Pubitemid 43794383)
18. Huang, M., Khor, E., Lim, L.Y., 2004. Uptake and cytotoxicity of chitosan molecules and nanoparticles: effects of molecular weight and degree of deacetylation. Pharm. Res. 21, 344-353. (Pubitemid 38221982)
19. Huang, T., Deng, C.H., Chen, N., Liu, Z., Duan, G.L., 2006. High performance liquid chromatography for the determination of glucosamine sulfate in human plasma after derivatization with 9-fluorenylmethyl chloroformate. J. Sep. Sci. 29, 2296-2302. (Pubitemid 44649643)
20. Ibrahim, A., Gilzad-kohan, M.H., Aghazadeh-Habashi, A., Jamali, F., 2012. Absorption and bioavailability of glucosamine in the rat. J. Pharm. Sci. 101, 2574-2583.
21. Ikeda, I., Sugano, M., Yoshida, K., Sasaki, E., Iwamoto, Y., Hatano, K., 1993. Effects of chitosan hydrolyzates on lipid absorption and on serum and liver lipid concentration in rats. J. Agric. Food Chem. 41, 431-435.
22. Illum, L., Farraj, N.F., Davis, S.S., 1994. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11, 1186-1189. (Pubitemid 24259861)
23. Illum, L., Watts, P., Fisher, A.N., Hinchcliffe, M., Norbury, H., Jabbal-Gill, I., Nankervis, R., Davis, S.S., 2002. Intranasal delivery of morphine. J. Pharmacol. Exp. Ther. 301, 391-400. (Pubitemid 34250318)
24. Jeong, J.M., Choi, C.H., 2007. Enhancement of paclitaxel transport and cytotoxicity by 7,3′,4′-trimethoxyflavone, a P-glycoprotein inhibitor. J. Pharm. Pharm. Sci. 10, 547-553.
25. Junginger, H.E., 2007. Excipients as absorption enhancers. In: Krishna, R., Yu, L. (Eds.), Biopharmaceutics Applications in Drug Development. Springer, New York, USA, pp. 139-174 (Chapter 6).
26. Kean, T., Roth, S., Thanou, M., 2005. Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J. Control. Release 103, 643-653. (Pubitemid 40471022)
27. Kean, T., Thanou, M., 2010. Biodegradation, biodistribution and toxicity of chitosan. Adv. Drug Deliv. Rev. 62, 3-11.
28. Klip, A., Paquet, M.R., 1990. Glucose transport and glucose transporters in muscle and their metabolic regulation. Diabetes Care 13, 228-243. (Pubitemid 20092110)
29. Kotze, A.F., Luessen, H.L., Thanou, M., Verhoef, J.C., de Boer, A.G., Juninger, H.E., Lehr, C.M., 1999. Chitosan and chitosan derivatives as absorption enhancers for peptide drugs across mucosal epithelia. In: Matiowitz, E., Chickering, D.E., Lehr, C.M. (Eds.), Bioadhesive Drug Delivery Systems: Fundamentals, Novel Approaches, and Development. Marcel Dekker, New York, USA, pp. 341-386.
30. Lafforgue, G., Arellano, C., Vachoux, C., Woodley, J., Philibert, C., Dupouy, V., Bousquet-Melou, A., Gandia, P., Houin, G., 2008. Oral absorption of ampicillin: role of paracellular route vs. PepT1 transporter. Fundam. Clin. Pharmacol. 22, 189-201. (Pubitemid 351392955)
31. Lehr, C.M., Bouwstra, J.A., Schacht, E.H., Junginger, H.E., 1992. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78, 43-48.
32. Leucuta, S.E., Vlase, L., 2006. Pharmacokinetics and metabolic drug interactions. Curr. Clin. Pharmacol. 1, 5-20.
33. Li, C.R., Zhang, L., Zhou, L.M., Wo, S.K., Lin, G., Zuo, Z., 2012. Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in Radix Scutellariae. AAPS J. 14, 23-34.
34. Lorenz, H., Richter, W., 2006. Osteoarthritis: cellular and molecular changes in degenerating cartilage. Prog. Histochem. Cytochem. 40, 135-163. (Pubitemid 43833326)
35. Luessen, H.L., de Leeuw, B.J., Langemeyer, M.W., de Boer, A.B., Verhoef, J.C., Junginger, H.E., 1996. Mucoadhesive polymers in peroral peptide drug delivery. VI. Carbomer and chitosan improve the intestinal absorption of the peptide drug buserelin in vivo. Pharm. Res. 13, 1668-1672. (Pubitemid 26426890)
36. Matheson, A.J., Perry, C.M., 2003. Glucosamine: a review of its use in the management of osteoarthritis. Drugs Aging 20, 1041-1060. (Pubitemid 37549879)
37. McCloy, R.F., Greenberg, G.R., Baron, J.H., 1984. Duodenal pH in health and duodenal ulcer disease: effect of a meal, Coca-Cola, smoking, and cimetidine. Gut 25, 386-392. (Pubitemid 14136459)
38. Meulyzer, M., Vachon, P., Beaudry, F., Vinardell, T., Richard, H., Beauchamp, G., Laverty, S., 2008. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthr. Cartil. 16, 973-979.
39. Morgan, D.M., Larvin, V.L., Pearson, J.D., 1989. Biochemical characterisation of polycation-induced cytotoxicity to human vascular endothelial cells. J. Cell Sci. 94, 553-559. (Pubitemid 20002853)
40. Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65, 55-63. (Pubitemid 14203433)
41. Murray, R.K., Keeley, F.W., 2009. The extracellular matrix. In: Murray, R.K., Kennelly, P.J., Rodwell, V.W., Botham, K.M., Bender, D.A., Weil, P.A. (Eds.), Harper's Illustrated Biochemistry. McGraw-Hill, New York, pp. 527-544 (Chapter 48).
42. Neuhoff, S., Ungell, A.L., Zamora, I., Artursson, P., 2003. pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm. Res. 20, 1141-1148. (Pubitemid 36951837)
43. Neuhoff, S., Ungell, A.L., Zamora, I., Artursson, P., 2005. pH-Dependent passive and active transport of acidic drugs across Caco-2 cell monolayers. Eur. J. Pharm. Sci. 25, 211-220. (Pubitemid 40725050)
44. Ng, S.P., Wong, K.Y., Zhang, L., Zuo, Z., Lin, G., 2005. Evaluation of the first-pass glucuronidation of selected flavones in gut by Caco-2 monolayer model. J. Pharm. Pharm. Sci. 8, 1-9. (Pubitemid 41528864)
45. Opanasopit, P., Aumklad, P., Kowapradit, J., Ngawhiranpat, T., Apirakaramwong, A., Rojanarata, T., 2007. Effect of salt forms and molecular weight of chitosans on in vitro permeability enhancement in intestinal epithelial cells (Caco-2). Pharm. Dev. Technol. 12, 447-455. (Pubitemid 350034877)
46. Persiani, S., Roda, E., Rovati, L.C., Locatelli, M., Giacovelli, G., Roda, A., 2005. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthr. Cartil. 13, 1041-1049. (Pubitemid 41672501)
47. Rossi, S., Ferrari, F., Bonferoni, M.C., Caramella, C., 2000. Characterization of chitosan hydrochloride-mucin interaction by means of viscosimetric and turbidimetric measurements. Eur. J. Pharm. Sci. 10, 251-257. (Pubitemid 30317460)
48. Rovati, L.C., Girolami, F., Persiani, S., 2012. Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties. Ther. Adv. Musculoskelet. Dis. 4, 167-180.
49. Russell, A.S., Aghazadeh-Habashi, A., Jamali, F., 2002. Active ingredient consistency of commercially available glucosamine sulfate products. J. Rheumatol. 29, 2407-2409. (Pubitemid 35266035)
50. Schipper, N.G.M., Olsson, S., Hoogstraate, J.A., deBoer, A.G., Varum, K.M., Artursson, P., 1997. Chitosans as absorption enhancers for poorly absorbable drugs. 2: mechanism of absorption enhancement. Pharm. Res. 14, 923-929. (Pubitemid 27326989)
51. Schipper, N.G.M., Varum, K.M., Artursson, P., 1996. Chitosans as absorption enhancers for poorly absorbable drugs. 1: influence of molecular weight and degree of acetylation on drug transport across human intestinal epithelial (Caco-2) cells. Pharm. Res. 13, 1686-1692. (Pubitemid 26426893)
52. Schipper, N.G.M., Varum, K.M., Stenberg, P., Ocklind, G., Lennernas, H., Artursson, P., 1999. Chitosans as absorption enhancers of poorly absorbable drugs. 3: influence of mucus on absorption enhancement. Eur. J. Pharm. Sci. 8, 335-343. (Pubitemid 29325026)
53. Setnikar, I., Palumbo, R., Canali, S., Zanolo, G., 1993. Pharmacokinetics of glucosamine in man. Arzneim.-Forsch. 43, 1109-1113. (Pubitemid 23311890)
54. Sinswat, P., Tengamnuay, P., 2003. Enhancing effect of chitosan on nasal absorption of salmon calcitonin in rats: comparison with hydroxypropyl- and dimethylbeta-cyclodextrins. Int. J. Pharm. 257, 15-22. (Pubitemid 36507028)
55. Smith, J., Wood, E., Dornish, M., 2004. Effect of chitosan on epithelial cell tight junctions. Pharm. Res. 21, 43-49. (Pubitemid 38122290)
56. Sugano, K., Kansy, M., Artursson, P., Avdeef, A., Bendels, S., Di, L., Ecker, G.F., Faller, B., Fischer, H., Gerebtzoff, G., Lennernaes, H., Senner, F., 2010. Coexistence of passive and carrier-mediated processes in drug transport. Nat. Rev. Drug Discov. 9, 597-614.
57. Takeuchi, H., Yamamoto, H., Niwa, T., Hino, T., Kawashima, Y., 1996. Enteral absorption of insulin in rats from mucoadhesive chitosan-coated liposomes. Pharm. Res. 13, 896-901. (Pubitemid 26227747)
58. Thanou, M., Verhoef, J.C., Junginger, H.E., 2001. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev. 52, 117-126. (Pubitemid 33079167)
59. Towheed, T.E., Anastassiades, T., 2007. Glucosamine therapy for osteoarthritis: an update. J. Rheumatol. 34, 1787-1790. (Pubitemid 350067633)
60. Towheed, T.E., Maxwell, L., Anastassiades, T.P., Shea, B., Houpt, J., Robinson, V., Hochberg, M.C., Wells, G., 2005. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst. Rev., CD002946.
61. Tu, J., Shen, Y., Mahalingam, R., Jasti, B., Li, X., 2010. Polymers in oral modified release systems. In: Wen, H., Park, K. (Eds.), Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice. John Wiley & Sons, Inc., Hoboken, NJ, USA, pp. 71-88.
62. Uchiyama, T., Sugiyama, T., Quan, Y.S., Kotani, A., Okada, N., Fujita, T., Muranishi, S., Yamamoto, A., 1999. Enhanced permeability of insulin across the rat intestinal membrane by various absorption enhancers: their intestinal mucosal toxicity and absorption-enhancing mechanism of n-lauryl-beta-D- maltopyranoside. J. Pharm. Pharmacol. 51, 1241-1250. (Pubitemid 30006463)
63. Uldry, M., Ibberson, M., Hosokawa, M., Thorens, B., 2002. GLUT2 is a high affinity glucosamine transporter. FEBS Lett. 524, 199-203. (Pubitemid 34804860)
64. Vllasaliu, D., Casettari, L., Fowler, R., Exposito-Harris, R., Garnett, M., Illum, L., Stolnik, S., 2012. Absorption-promoting effects of chitosan in airway and intestinal cell lines: a comparative study. Int. J. Pharm. 430, 151-160.
65. Zhang, L., Chow, M.S., Zuo, Z., 2006. Effect of the co-occurring components from green tea on the intestinal absorption and disposition of green tea polyphenols in Caco-2 monolayer model. J. Pharm. Pharmacol. 58, 37-44. (Pubitemid 43041994)
66. Zhang, L., Lin, G., Kovacs, B., Jani, M., Krajcsi, P., Zuo, Z., 2007. Mechanistic study on the intestinal absorption and disposition of baicalein. Eur. J. Pharm. Sci. 31, 221-231. (Pubitemid 46818982)
67. Zhou, W., Qin, K.M., Shan, J.J., Ju, W.Z., Liu, S.J., Cai, B.C., Di, L.Q., 2012. Improvement of intestinal absorption of forsythoside A in weeping forsythia extract by various absorption enhancers based on tight junctions. Phytomedicine 20, 47-58.